Maccura Biotechnology Co Ltd
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such a… Read more
Maccura Biotechnology Co Ltd (300463) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.61 Billion CNY
Based on the latest financial reports, Maccura Biotechnology Co Ltd (300463) has total liabilities worth CN¥1.61 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Maccura Biotechnology Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Maccura Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Maccura Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Maccura Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vital Farms Inc
NASDAQ:VITL
|
USA | $167.48 Million |
|
SkyCity Entertainment Group Limited
PINK:SKYZF
|
USA | $1.43 Billion |
|
Intellect Design Arena Limited
NSE:INTELLECT
|
India | ₹11.07 Billion |
|
Shaanxi Ligeance Mineral Resources Co Ltd
SHE:000697
|
China | CN¥3.95 Billion |
|
Chang Wah Technology Co Ltd
TWO:6548
|
Taiwan | NT$11.37 Billion |
|
Phreesia Inc
NYSE:PHR
|
USA | $103.14 Million |
|
Janux Therapeutics Inc
NASDAQ:JANX
|
USA | $48.21 Million |
|
Antin IP SA
PA:ANTIN
|
France | €127.37 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Maccura Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maccura Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maccura Biotechnology Co Ltd (2011–2024)
The table below shows the annual total liabilities of Maccura Biotechnology Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.55 Billion | +2.98% |
| 2023-12-31 | CN¥1.51 Billion | -7.62% |
| 2022-12-31 | CN¥1.63 Billion | -19.40% |
| 2021-12-31 | CN¥2.03 Billion | -14.17% |
| 2020-12-31 | CN¥2.36 Billion | +8.77% |
| 2019-12-31 | CN¥2.17 Billion | +28.24% |
| 2018-12-31 | CN¥1.69 Billion | +74.36% |
| 2017-12-31 | CN¥970.12 Million | +133.76% |
| 2016-12-31 | CN¥415.01 Million | +11.65% |
| 2015-12-31 | CN¥371.71 Million | -12.39% |
| 2014-12-31 | CN¥424.27 Million | +82.46% |
| 2013-12-31 | CN¥232.53 Million | +24.66% |
| 2012-12-31 | CN¥186.54 Million | -3.54% |
| 2011-12-31 | CN¥193.39 Million | -- |